

Arden and Greater East Midlands Commissioning Support Unit in association with
Lincolnshire Clinical Commissioning Groups, Lincolnshire Community Health Services,
United Lincolnshire Hospitals Trust and Lincolnshire Partnership Foundation Trust

Lincolnshire *PACE* Shorts

Summary of PACEF decisions from October 2015

For further details see *PACE Bulletin* Volume 9 No 18 (October 2015)

Drug	Indication(s)	Traffic Light and <i>Joint Formulary</i> Status
Aflibercept 40mg/ml solution for injection (Eylea) (Bayer)	For the treatment of visual impairment due to diabetic macular oedema	RED Approved for inclusion in the Lincolnshire Joint Formulary subject to specific NICE treatment criteria
Dexamethasone 700 microgram intravitreal implant (Ozurdex) (Allergan)	For the treatment of visual impairment due to diabetic macular oedema (DME) in patients who are who are pseudophakic or who are considered insufficiently responsive to, or unsuitable for, non-corticosteroid therapy.	RED Approved for inclusion in the Lincolnshire Joint Formulary subject to specific NICE treatment criteria
Dulaglutide 750 microgram/0.5ml and 1.5mg/0.5ml in a pre-filled pen (Trulicity) (Lilly)	For the treatment of type 2 diabetes mellitus inadequately controlled by diet and exercise: as monotherapy when metformin is inappropriate, or with other hypoglycaemics including insulin, when these alone are inadequate.	GREEN Approved for inclusion in the Lincolnshire Joint Formulary subject to specific criteria: (1) it should only be initiated by specialist diabetes services, GPs with a special interest in diabetes or GPs with a high level of experience in the treatment of diabetes; (2) it should be reserved for those who are appropriate for weekly treatment and intolerant to once weekly exenatide or unable to use the Bydureon device.
Exenatide 2mg powder and solvent for sustained release suspension for injection pre-filled pen (Bydureon) (AstraZeneca)	For use as an adjunct to existing therapy in type 2 diabetes where glycaemic control is inadequate used either as dual therapy with metformin, a sulfonylurea or a glitazone or as triple therapy with metformin and a sulfonylurea or a glitazone.	GREEN Approved for inclusion in the Lincolnshire Joint Formulary. Subject to a second line role after first line twice daily exenatide (Byetta) or once daily liraglutide (Victoza)
Meningococcal group ACWY conjugate vaccine (Menveo) (Novartis Vaccines)	For active immunization of children (from 2 years of age), adolescents and adults at risk of exposure to <i>Neisseria meningitidis</i> groups A, C, W135 and Y, to prevent invasive disease.	GREEN Included in the Lincolnshire Joint Formulary. Should be prescribed on the NHS as part of the national vaccination programme for adolescents. May also be indicated in certain high risk groups.
Meningococcal group ACWY conjugate vaccine (Nimenrix) (GlaxoSmithKline)	For active immunisation of individuals from the age of 12 months and above against invasive meningococcal diseases caused by <i>Neisseria meningitidis</i> group A, C, W-135 and Y.	GREEN Included in the Lincolnshire Joint Formulary. Should be prescribed on the NHS as part of the national vaccination programme for adolescents. May also be indicated in certain high risk groups.
Meningococcal group B vaccine (Bexsero) (Novartis Vaccines)	For active immunisation against invasive disease cause by <i>Neisseria meningitidis</i> group B.	GREEN Included in the Lincolnshire Joint Formulary. Should only be prescribed on the NHS as part of the national vaccination programme for infants aged from 2 months and for the management of outbreaks of invasive meningococcal disease where the vaccine may be prescribed for close contacts of cases following a request from a Public Health England consultant or nurse. May also be indicated in the same high risk groups that are currently offered ACWY conjugate vaccine.

Secukinumab 150mg injection (Cosentyx) (Novartis)	For the treatment of moderate to severe plaque psoriasis in adults	RED Approved for inclusion in the Lincolnshire Joint Formulary subject to specific NICE treatment criteria:
---	--	---

RED-RED: This signifies that a product is **not recommended** for prescribing in **either** primary or secondary care. All new products are classified as RED-RED pending assessment by PACEF.

RED: This signifies that a product has been approved for use within secondary care, tertiary care or a primary care hosted specialist service only and **should not be routinely prescribed in primary care**. RED drugs may be used within ULHT or LPFT subject to approval for use within each Trust. ULHT and LPFT reserve the right to determine whether or not RED drugs will be used within their Trusts. RED classification does not automatically signify that a drug will be available within secondary/tertiary care.

AMBER: This signifies that a drug has been approved for use in primary care **subject to specialist initiation; a shared care guideline (SCG) may also be required**. The main purpose of the SCG will be to clearly define both specialist and GP responsibilities. Not all AMBER drugs that require SCGs are currently covered by formal documents; PACEF are working to rectify this.

GREEN: This signifies a product that is **approved for initiation in either primary or secondary care**.

This bulletin has been created specifically to convey details of decisions taken at the Prescribing and Clinical Effectiveness Forum (PACEF) to all stakeholders across the Lincolnshire Healthcare Community in both primary and secondary care. Back issues of the *PACE Bulletin* and *PACE Shorts* are available through the PACEF website (<http://lincolnshire-pacef.nhs.uk>); follow the commissioning link to PACEF. Electronic copies of the *PACE Bulletin* are circulated to a wide readership via email. If you are not currently on our distribution list and wish to receive regular copies of PACEF publications please contact Sandra France on sandra.france@gemcsu.nhs.uk.

Google searching can be a quick and effective way of finding back numbers of the *PACE Bulletin* relevant to a specific topic of interest. Searchers are advised to use the official version of the *Bulletin* available from the PACEF website rather than depend on a potentially unreliable draft or variant found through Google or an alternative search engine.

The *Lincolnshire Joint Formulary* is available on line and is fully searchable; it can be accessed at www.lincolnshirejointformulary.nhs.uk

THIS DOCUMENT IS INTENDED FOR USE BY NHS HEALTHCARE PROFESSIONALS ONLY AND CANNOT BE USED FOR COMMERCIAL OR MARKETING PURPOSES WITHOUT PERMISSION